Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02564523
Recruitment Status : Completed
First Posted : September 30, 2015
Last Update Posted : March 20, 2019
Sponsor:
Collaborator:
EBOVAC2 Consortium
Information provided by (Responsible Party):
Janssen Vaccines & Prevention B.V.

Brief Summary:
The purpose of this study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo. The study will include healthy adults and elderly participants, HIV infected participants and healthy children in 2 age strata.

Condition or disease Intervention/treatment Phase
Hemorrhagic Fever, Ebola Biological: Ad26.ZEBOV Biological: MVA-BN-Filo Biological: Placebo Phase 2

Detailed Description:
This is a randomized, observer-blind, placebo-controlled, parallel-group, multicenter, Phase 2 study evaluating the safety, tolerability and immunogenicity of 3 heterologous prime-boost regimens using Ad26.ZEBOV as prime and MVA-BN-Filo as boost vaccination, administered at 28-, 56- and 84-day (Group 1, 2 and 3 as above) intervals, in healthy adults and elderly participants. A 28- and 56-day (Groups 1 and 2, as above) schedule will be evaluated in HIV-infected participants and in healthy children in 2 age strata. The study consists of a screening phase of up to 8 weeks, a vaccination phase in which participants will be vaccinated at baseline (Day 1) followed by a boost vaccination on Day 29, 57 or 85, a post-vaccination phase and long-term follow-up phase until Day 365. Participants in Cohort 1 substudy (Group 1 and 2) who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination). All participants within a cohort will be followed in a blinded manner by the site until the last subject in that cohort has completed the study. This study will be conducted in Africa and the enrollment will take place sequentially in three cohorts: the first cohort will consist of healthy participants (18 - 70 years); the second cohort (2a) will include HIV-infected participants (18 to 50 years) and healthy children 12 to 17 years (cohort 2b); the third cohort will include children aged 4 to 11 years inclusive will be enrolled. Within each cohort, participants will be randomized in a 5:1 ratio to receive active vaccine versus placebo. Safety evaluations will include assessments of adverse events, an electrocardiogram (ECG) for adult participants at screening, physical examination, vital signs (blood pressure, pulse/heart rate, body temperature), clinical laboratory and pregnancy testing. An independent data monitoring committee (IDMC) will be established to monitor data on a regular basis to ensure the continuing safety of the participants enrolled in the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1075 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa
Actual Study Start Date : November 6, 2015
Actual Primary Completion Date : February 12, 2019
Actual Study Completion Date : February 12, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ebola HIV/AIDS

Arm Intervention/treatment
Experimental: Group 1
Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
Biological: Ad26.ZEBOV
One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles)

Biological: MVA-BN-Filo
One 0.5 mL IM injection of (1x10*8 infectious units)

Biological: Placebo
One 0.5 mL IM injection of 0.9% saline

Experimental: Group 2
Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 57) or placebo (Day 1/Day 57) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
Biological: Ad26.ZEBOV
One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles)

Biological: MVA-BN-Filo
One 0.5 mL IM injection of (1x10*8 infectious units)

Biological: Placebo
One 0.5 mL IM injection of 0.9% saline

Experimental: Group 3
Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 85) or placebo (Day 1/Day 85)
Biological: Ad26.ZEBOV
One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles)

Biological: MVA-BN-Filo
One 0.5 mL IM injection of (1x10*8 infectious units)

Biological: Placebo
One 0.5 mL IM injection of 0.9% saline




Primary Outcome Measures :
  1. Number of Participants With Adverse Events [ Time Frame: Up to 42 +/-3 days post-last vaccination ]
  2. Number of Participants With Serious Adverse Events [ Time Frame: Continuous throughout the duration of the study (up to Day 365 +/- 1 month) ]
  3. Number of Participants with Solicited Local and Systemic Adverse Events [ Time Frame: Up to 7 days after each study vaccination ]

Secondary Outcome Measures :
  1. Antibody levels against the EBOV GP measured by an enzyme-linked immunosorbent assay (ELISA) [ Time Frame: At 21 days post boost vaccination ]
  2. Number of Participants With Adverse Events as a Measure of Safety and Tolerability of a Third Vaccination With Ad26.ZEBOV [ Time Frame: Up to 28 Days after third vaccination ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Criteria for healthy adults and elderly participants:

  • Participant must be healthy in the investigator's clinical judgment on the basis of clinical laboratory tests, medical history, ECG, physical examination and vital signs performed at screening. Participants with hemoglobin values outside the local laboratory reference ranges may be included if the hemoglobin is above the age/gender specific limits
  • Female participants of childbearing potential must use adequate birth control measures, must have a negative pregnancy test at screening and immediately prior to each study vaccination
  • A man who is sexually active with a woman of childbearing potential must be willing to use condoms for sexual intercourse beginning prior to enrollment, unless a vasectomy was performed more than 1 year prior to screening
  • Participant must pass the test of understanding (TOU)
  • Participant must be available and willing to participate for the duration of the study visits and follow-up, provide verifiable identification, and have a means to be contacted Additional Inclusion Criteria HIV-infected Participants
  • Participant must be between 18 to 50 years of age and must have a documented HIV-infection for at least 6 months prior to screening
  • Participant must be on a stable 3 drug regimen of Highly Active Antiretroviral Therapy for at least 4 weeks prior to screening and having a CD4 positive cell count of >350 cells/microliter. Also participant must be in an otherwise reasonable good medical condition Additional Inclusion Criteria Children Participants
  • Parent/legal guardian must pass the TOU before signing the inform consent form. Informed assent must be obtained from adolescents and older children, depending on local regulations and practice
  • Pediatric participant's age on the day of randomization must be within one of the 2 age strata: 12-17 years or 4-11 years (all ages inclusive)
  • Pediatric participants must have received all routine immunizations appropriate for his or her age as reported by the parent(s)/legal guardian, according to local routine vaccination schedules

Exclusion criteria:

  • Diagnosed with Ebola virus disease or previously exposed to Ebola virus including travel to epidemic Ebola areas less than 1 month prior to screening
  • Having received any candidate Ebola vaccine or any experimental candidate Ad26- or MVA-based vaccine in the past
  • Having HIV type 1 or type 2 infection (for healthy adults/elderly/children)
  • Pediatric participants with weight-per-height below 10th percentile according to the Centers for Disease Control and Prevention (CDC) growth charts (4- to 11-year-olds)
  • A woman who is pregnant, breast-feeding or planning to become pregnant while enrolled in the study or within at least 3 months after the prime vaccination or up to 1 month after the boost vaccination (whichever takes longer) or within at least 3 months after the third vaccination
  • For HIV+ adults, no AIDS-defining illnesses

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02564523


Locations
Layout table for location information
Burkina Faso
Bobodioulasso, Burkina Faso
Ouagadougou, Burkina Faso
Côte D'Ivoire
Abidjan, Côte D'Ivoire
Toupah/Ousrou, Côte D'Ivoire
Kenya
Nairobi, Kenya
Uganda
Entebbe, Uganda
Kampala, Uganda
Sponsors and Collaborators
Janssen Vaccines & Prevention B.V.
EBOVAC2 Consortium
Investigators
Layout table for investigator information
Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial Janssen Vaccines & Prevention B.V.

Layout table for additonal information
Responsible Party: Janssen Vaccines & Prevention B.V.
ClinicalTrials.gov Identifier: NCT02564523     History of Changes
Other Study ID Numbers: CR107249
VAC52150EBL2002 ( Other Identifier: Janssen Vaccines & Prevention B.V. )
First Posted: September 30, 2015    Key Record Dates
Last Update Posted: March 20, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Janssen Vaccines & Prevention B.V.:
Healthy
Vaccine
Ebola viruses
Ebola virus disease (EVD)
Filoviruses
Hemorrhagic fever
Monovalent vaccine
Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
Safety
Immunogenicity

Additional relevant MeSH terms:
Layout table for MeSH terms
Hemorrhagic Fever, Ebola
Hemorrhagic Fevers, Viral
HIV Seropositivity
RNA Virus Infections
Virus Diseases
Filoviridae Infections
Mononegavirales Infections
HIV Infections
Lentivirus Infections
Retroviridae Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs